CLEOCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE)
CLEOCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: CLEOCIN PHOSPHATE; Generic name: CLINDAMYCIN PHOSPHATE; Manufacturer: Henry Schein, Inc..
| Brand name | CLEOCIN PHOSPHATE |
|---|---|
| Generic name | CLINDAMYCIN PHOSPHATE |
| Manufacturer | Henry Schein, Inc. |
| Used for | INDICATIONS AND USAGE CLEOCIN PHOSPHATE products are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. CLEOCIN PHOSPHATE products are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives ( |
| Dosage | DOSAGE AND ADMINISTRATION If diarrhea occurs during therapy, this antibiotic should be discontinued (see WARNING BOX ). Clindamycin phosphate IM administration should be used undiluted. Clindamycin phosphate IV administration should be diluted (see DILUTION FOR IV USE AND IV INFUSION RATES below). Adults Parenteral (IM or IV Administration) Serious infections due to aerobic gram-positive cocci and the more susceptible anaerobes (NOT generally including Bacteroides fragilis, Peptococcus species a |
| Warnings | WARNINGS See BOXED WARNING. Clostridioides difficile-Associated Diarrhea Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strai |
| Active ingredient(s) | CLINDAMYCIN PHOSPHATE |
| Route | INTRAMUSCULAR |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=184acaee-6129-479e-850f-d89575b8b391 |